Doctor Reacts to Viral Peptide Misinformation
A urologist plays clips of a podcast guest attacking peptides, including BPC-157, and answers each claim point by point with the data he cites.
With Dr. Alex Tatem (board-certified urologist, fellowship-trained in men's health), Luisa Nicola
Key moments
Tap a moment to play the video from there.
- 0:00Setting up the reactionTatem introduces the Shawn Ryan episode clips, his background, and why he thinks the claims could influence regulators and patient access.
- 2:43No human trials on peptidesHe lists insulin, semaglutide, tirzepatide and other peptide drugs with large randomized trials, and calls the claim false.
- 4:38What 'against peptides' meansTatem says peptide is just a chain of amino acids, covering insulin, oxytocin, vasopressin and GLP-1 drugs, so blanket opposition is not a scientific position.
- 6:29BPC-157 and cancer argumentHe grants that BPC-157 promotes angiogenesis, then argues the cancer leap is unsupported and applies selectively, comparing it to exercise and estrogen.
- 12:02Was BPC-157 shut down by FDAHe says no FDA shutdown happened, describes two human trials sponsored by Croatian companies, and mentions the removal from the category two list.
- 15:04The Huberman correction storyTatem says the episode she cited discusses anti-amyloid antibody drugs, not melanotan or BPC-157, and that antibodies are not peptides.
- 18:13Gray market and final thoughtsHe agrees sourcing quality is a real issue, argues restriction removes oversight, and compares the debate to growth hormone in 1990.
What the video says
Dr. Alex Tatem, who describes himself as a board-certified urologist working in men's health, TRT and peptides, reacts to clips from a guest named Luisa Nicola on the Shawn Ryan show. He plays what she said, then walks through what he says the published record shows. The format is a rebuttal, and he states plainly that he thinks she is wrong.
He takes four claims in turn. On the idea that no human randomized trial has been done on peptides, he lists approved peptide drugs such as insulin, semaglutide and tirzepatide, cites trial names and enrollment sizes, and says each has phase three data. On "I'm against peptides," he argues that a peptide is simply a short chain of amino acids, so the category spans insulin, oxytocin, vasopressin and GLP-1 drugs. On BPC-157 and cancer, he agrees the compound promotes angiogenesis, but argues that leaping from better blood flow to feeding hidden tumors is unsupported. He separates normal angiogenesis from tumor angiogenesis, mentions preclinical colitis-associated cancer models he calls anti-tumor, and says he knows of no documented human cancer cases. He also concedes there is no prospective cohort data on cancer incidence in users.
On the claim that the FDA shut down BPC-157 trials, he says no such record exists. He describes two human trials, both sponsored by Croatian companies tied to the same researcher, and says the lack of independent replication is a legitimate criticism. He also says the FDA recently removed BPC-157 from its category two list after the nominations were withdrawn. In the last segment he disputes Nicola's account of a correction from Huberman, saying the episode she cited was about antibody drugs for Alzheimer's rather than peptides, and that her melanotan explanation is also wrong.
He closes by agreeing that gray market sourcing is a real problem, but argues the answer is a clean, regulated supply rather than restriction. Nicola's side is heard only in clips chosen by the host, and his own figures are not independently checked in the video.
On each compound
BPC-1576:29
Tatem says BPC-157 promotes angiogenesis but argues that does not mean it fuels cancer, citing preclinical colitis-associated cancer models and no documented human cancer cases. He says its two human trials were sponsored by Croatian companies tied to one researcher and lack independent replication.
See how your DNA reads BPC-157Melanotan II17:47
Tatem says the guest's claim of a phase two melanotan death is wrong. According to him, Clinuvel halted phase two development over hypertension and sexual dysfunction, with no documented trial fatality.
See how your DNA reads Melanotan IISemaglutide2:43
Tatem cites SUSTAIN 6, SELECT and STEP 1 as randomized trials of semaglutide, using them to show that peptide drugs have large human trial data.
See how your DNA reads Semaglutide“Restriction does not eliminate use, it eliminates oversight.”
What this video doesn’t settle
- The video does not establish whether BPC-157 is safe or effective in humans, and Tatem himself says independent human trials do not exist.
- Nicola's claims appear only as short clips chosen by the host, so her full arguments and context are not shown.
- Trial names, enrollment figures, regulatory dates and the Huberman transcript check are stated by Tatem and not documented on screen.
Questions this video answers
Does BPC-157 cause cancer according to this video?
Tatem says no human cancer cases have been documented despite millions of gray market doses, and describes preclinical models he calls anti-tumor. He also says there is no prospective cohort data showing an increase or decrease in cancer incidence among users.
Has the FDA shut down BPC-157 trials?
Tatem says there is no record of this. He states the human trials took place outside the US with no IND on file, and that the earlier program ended after company acquisitions.
Have there been human trials of BPC-157?
Tatem describes two attempts: a phase one and a phase two program in ulcerative colitis, with the full manuscripts never published, and a phase one in 42 healthy volunteers in Tijuana whose submission was pulled. He notes both involved the same Croatian-linked researcher.
Are peptides as a class dangerous?
Tatem argues the question makes little sense because peptides include insulin, oxytocin, GLP-1 drugs and many others. He says the category is among the widest in medicine.
What does Tatem say about gray market peptides?
He agrees that studies have found some gray market products may be contaminated or mislabeled in concentration. His position is that a clean, regulated supply is the fix, and that restriction pushes patients toward worse sourcing.
Video by Dr. Alex Tatem on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
